Trimpex™ (trimethoprim) – New drug approval
October 7, 2017 – Key Therapeutics received FDA approval of Trimpex (trimethoprim) oral solution, for pediatric patients for the treatment of acute otitis media due to susceptible strains of Streptococcus pneumoniae and Haemophilus influenza, and for adult patients for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species and coagulase-negative Staphylococcus species, including S. saprophyticus.
Top